- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06328543
Itch Sensation Induced by Multiple Applications of Pruritogens (temporal Summation)
November 20, 2024 updated by: Silvia Lo Vecchio, Aalborg University
Repetitive Applications of Pruritogens and Effects of a Cutaneous-induced Pain Stimulation on Nonhistaminergic Itch Perception
In This experiment, the investigators would like to design a new itch model based on the temporal summation of pruritic stimuli.
The hypothesis behind this study (temporal summation) is that two overlapped applications of pruritogens will result in a higher itch sensation compared with a single application.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals.
Furthermore, there is a lack of efficient treatment options for chronic itch.
In order to mimic a clinical itch condition as presented in patients, the aim of the project is to investigate a new itch model based on the multiple applications of pruritogens (temporal summation).
In particular, the purpose is to evaluate if a single application of cowhage/histamine (non-histaminergic and histaminergic itch, respectively) results in a lower itch sensation compared with two overlapped applications of the pruritogens on the same area.
Study Type
Interventional
Enrollment (Estimated)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Silvia Lo Vecchio, PhD
- Phone Number: +4521397785
- Email: slv@hst.aau.dk
Study Contact Backup
- Name: Giulia Erica Aliotta, PhD
- Phone Number: 50290580
- Email: gea@hst.aau.dk
Study Locations
-
-
-
Aalborg, Denmark, 9260
- Recruiting
- Aalborg University
-
Contact:
- Silvia Lo Vecchio, PhD
-
Contact:
- Silvia Lo Vecchio, PhD
- Phone Number: 0045+21397785
- Email: slv@hst.aau.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy men and women
- 18-60 years
- Speak and understand Englis
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other addictive drugs
- Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder, or mental illnesses that may affect the results
- Lack of ability to cooperate
- Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids
- Skin diseases (e.g. atopic dermatitis, pruritus nodularis, eczema, psoriasis)
- Moles, scars, or tattoos in the area to be treated or tested.
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1st pruritogen
The subproject is conducted in 1 session (approx.
3 hours in total) divided into two parts.
In the first part, 3 test areas (3x3 cm) will be selected on one forearm of the subject.
The 3 areas will be randomly treated with 1 application of cowhage, 2 applications of cowhage (the second application will be conducted 90 seconds after the first one in the same area), and 2 applications of cowhage (the second application will be conducted 180 seconds after the first one in the same area).
Itch will be monitored using a VAS (visual analog scale) for 15 min in each session.
After the removal of cowhage, FLPI, alloknesis, and mechanically evoked itch will be measured.
|
Histaminergic itch will be evoked by a 1% histamine solution.
A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
|
|
Experimental: 2nd pruritogen
The second part will be conducted 20 minutes after the first part, and the procedure will be the same, but using histamine instead of cowhage.
The two parts will be randomized between subjects.
|
25 spicules will be inserted in the center of the predefined skin area on the mandibular area.
The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of itch
Time Frame: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet.
The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'.
|
1 minute after every itch inductions
|
|
Assessment of pain
Time Frame: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet.
The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'
|
1 minute after every itch inductions
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microvascular reactivity
Time Frame: 10 minutes after every itch inductions
|
The evoked cutaneous inflammation (quantified by superficial blood perfusion) will be measured by full-field laser perfusion imaging.
|
10 minutes after every itch inductions
|
|
Alloknesis
Time Frame: 12 minutes after every itch inductions
|
Alloknesis sensation is measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN.
|
12 minutes after every itch inductions
|
|
Mechanically evoked itch
Time Frame: 15 minutes after every itch inductions
|
Mechanically evoked itch is measured using three von Frey filaments of 4.08, 4.16 and 4.31 (1.0, 1.4, 2.0 g, respectively) (North Coast Medical, Gilroy, CA).
The center of the skin area is stimulated by 3 pricks, repeated 3 times in short succession.
After a total of 9 stimulations, the participants will report the itch elicited on a numerical rating scale (NRS) from 0 to 10 (0 = "no itch"; 10 = "worst imaginable itch").
|
15 minutes after every itch inductions
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
March 19, 2024
First Submitted That Met QC Criteria
March 22, 2024
First Posted (Actual)
March 25, 2024
Study Record Updates
Last Update Posted (Estimated)
November 22, 2024
Last Update Submitted That Met QC Criteria
November 20, 2024
Last Verified
November 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20210046 4th project
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Histamine
-
University GhentResearch Foundation FlandersCompletedExercise | HistamineBelgium
-
AB BiotekHospital Clinic of BarcelonaCompleted
-
Children's Mercy Hospital Kansas CityWithdrawn
-
University of British ColumbiaRecruiting
-
University GhentResearch Foundation FlandersRecruiting
-
IPSC AGMedical University of Graz; Sciotec Diagnostic Technologies GmbHCompletedHistamine IntoleranceAustria
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
-
BayerCompletedHistamine H1 Antagonists, Non-SedatingGermany
-
Complexo Hospitalario Universitario de A CoruñaCompletedLower Urinary Tract Symptoms | Histamine IntoleranceSpain
-
North Texas Institute for Clinical TrialsCompletedHistamine Responsive Allergy PatientsUnited States
Clinical Trials on Cowhage
-
Aalborg UniversityRecruitingPain, Burning | CapsaicinDenmark
-
Aalborg UniversityRecruiting
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
-
Aalborg UniversityCompleted
-
Aalborg UniversityRecruitingHistamine | CowhageDenmark
-
Aalborg UniversityRecruitingSleep Fragmentation | Histamine | CowhageDenmark
-
Aalborg UniversityRecruitingSleep Deprivation | Histamine | CowhageDenmark
-
Aalborg UniversityNot yet recruiting
-
Aalborg UniversityRecruiting
-
Aalborg UniversityActive, not recruiting